Showing 2281-2290 of 3223 results for "".
- Alcon to Showcase New Products, Commitment to ECP Education at 2018 Optometry’s Meetinghttps://modernod.com/news/alcon-to-showcase-new-products-commitment-to-ecp-education-at-2018-optometrys-meeting/2480083/Alcon will introduce new products and educational resources to eye care professional (ECP) and paraoptometric audiences at this year’s American Optometric Association (AOA) Optometry’s Meeting taking place June 20-24 in Denver. Notably, Leatrice Eiseman, executive director at the Pantone C
- Allergan Announces Former Abbott Executive to Join Board of Directors as Part of “Refreshment Process”https://modernod.com/news/allergan-announces-former-abbott-executive-to-join-board-of-directors-as-part-of-refreshment-process/2480087/Allergan on Thursday said that former Abbott Laboratories executive Thomas Freyman will be joining its board with immediate effect. CEO Brent Saunders remarked “[Freyman] has nearly four decades of industry experience including finance leadership and serving on multiple public boards, makin
- Allergan Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR Implanthttps://modernod.com/news/allergan-announces-positive-topline-phase-3-clinical-data-for-bimatoprost-sr-implant/2480095/Allergan announced the release of new topline clinical trial data on Bimatoprost SR, a sustained-release, biodegradable implant for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. Bim
- Alcon Launches Social Media Campaign to Educate Cataract Patients on Treatment Optionshttps://modernod.com/news/alcon-launches-social-media-campaign-to-educate-cataract-patients-on-treatment-options/2480106/Alcon is launching a digital campaign, “See What You’re Missing,” to empower people to overcome the “FOMO” (fear of missing out) that can be associated with living with cataracts. The new campaign, launched during Cataract Awareness Month, will arm millions of Americans with information to
- Eyenovia Receives Notices of Allowance from USPTO on Two Additional Patent Applications for Ophthalmic Drug Deliveryhttps://modernod.com/news/eyenovia-receives-notices-of-allowance-from-uspto-on-two-additional-patent-applications-for-ophthalmic-drug-delivery/2480109/Eyenovia announced it has received Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for two additional patent applications. The allowed patents provide fundamental coverage on physiologic microdroplet ejection diameters and velocities, which enable gentle delivery of ophthal
- Allergan Shareholders Urge Company to Overhaul Management Structure; Split Role of Chairman and CEOhttps://modernod.com/news/allergan-shareholders-urge-company-to-overhaul-management-structure-split-role-of-chairman-and-ceo/2480116/In a letter sent to Allergan’s board of directors on Tuesday, two company shareholders, Appaloosa Management and Senator Investment Group, called on the drugmaker to divide the roles of chief executive officer and chairman, currently held by Brent Saunders. The investors also urged Allergan
- Allergan Plans Sales of Women’s Health, Infectious Disease Unitshttps://modernod.com/news/allergan-plans-sales-of-womens-health-infectious-disease-units/2480131/Allergan plans to sell off its women’s health and infectious disease businesses as Chief Executive Brent Saunders works to end the steep slide in its share price over the last year, according to a
- Retinal Changes on OCT Angiography May Flag Early Alzheimer’shttps://modernod.com/news/retinal-changes-on-oct-angiography-may-flag-early-alzheimers/2480158/Microvascular changes in the retina detected by using noninvasive optical coherence tomography (OCT) angiography align well with imaging and biomarker evidence of preclinical Alzheimer’s disease, a new study shows, according to a Medscape
- Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globallyhttps://modernod.com/news/alcon-cares-project-100-commits-to-reducing-cataract-blindness-globally/2480168/Alcon announced Alcon Cares Project 100, which aims to reduce cataract blindness by providing equipment to perform phaco surgeries. Alcon Cares, a foundation that oversees equipment and product donations to those in need, will give 100 rep
- Sylentis Announces New Data on the Treatment of Allergic Conjunctivitishttps://modernod.com/news/sylentis-announces-new-data-on-the-treatment-of-allergic-conjunctivitis/2480172/At the ARVO meeting, Sylentis presented preclinical results on its RNAi therapy, demonstrating how SYL116011 acts on seasonal ocular allergies SYL116011, which is being researched for ocular allergies caused by pollen, reduces the symptoms related to allergy, such as swelling and tearing,